Who is sponsoring NCT03183479?

NCT03183479 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT03183479?

Interventions in NCT03183479: Fibrinogen Concentrate Human, Normal saline.

What condition does NCT03183479 study?

NCT03183479 studies Scoliosis; Adolescence, Bleeding, Surgery.

Is NCT03183479 still recruiting?

NCT03183479 is currently completed. Last updated 2 March 2020.

Last reviewed 2020-03-02 · How we verify

NCT03183479

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery

Completed Phase 4 Last updated 2 March 2020

What this trial tests

Phase 4 trial testing Fibrinogen Concentrate Human in Scoliosis; Adolescence in 102 participants. Completed in 31 August 2019.

Timeline

14 June 2017

Primary endpoint
31 August 2019

31 August 2019

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	102
Start date	14 June 2017
Primary completion	31 August 2019
Estimated completion	31 August 2019
Sites	1 location across China

Drugs / interventions tested

Fibrinogen Concentrate Human — full drug profile →
Normal saline

Conditions studied

Scoliosis; Adolescence — all drugs for Scoliosis; Adolescence →
Bleeding — all drugs for Bleeding →
Surgery — all drugs for Surgery →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 12 to 18, any sex, with Scoliosis; Adolescence or Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Allogeneic blood products transfusions are often necessary to treat perioperative bleeding in patients undergoing complex scoliosis surgeries. A prospective, randomized trial is designed to evaluate if the infusion of fibrinogen concentrate may reduce allogeneic blood transfusion in patients undergoing scoliosis surgery. Eligible patients will be randomly assigned to treatment group (fibrinogen concentrate infusion) and control group (normal saline infusion), and functional fibrinogen will be measured to guide the infusion of fibrinogen concentrate. Perioperative blood loss, intraoperative blood loss, and the amount of perioperative allogeneic blood transfusion will be compared between the two groups to determine the effect of fibrinogen concentrate infusion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia.
Fabes J, Brunskill SJ, Curry N, Doree C, et al · · 2018 · cited 11× · PMID 30582172 · DOI 10.1002/14651858.cd010649.pub2

Verify or expand the search:

Other trials of Fibrinogen Concentrate Human

Trials testing the same drug.

NCT05391412 — Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery · Phase 4 · unknown
NCT05091684 — Administration of Fibrinogen Concentrate for Refractory Bleeding · Phase 2 · terminated
NCT04434001 — ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery · Phase 2 · terminated
NCT03784794 — Patient Blood Management for Massive Obstetric Hemorrhage · NA · completed

Other recruiting trials for Scoliosis; Adolescence

Currently open trials in the same condition.

NCT06242821 — Yoga for Back Pain in Adolescent Scoliosis · NA · recruiting
NCT06884150 — fNIRS-based Analysis and Evaluation of the Effect of Schroth Rehabilitation on Motor Functions in Adolescent Idiopathic · NA · active not recruiting
NCT06416579 — Comparison of the Efficiency of Schroth Method and Virtual Reality Exercises in Individuals With AIS · NA · recruiting
NCT06093477 — Studying Melatonin and Recovery in Teens · NA · recruiting
NCT05819034 — Conservative Management for Adolescent Idiopathic Scoliosis · NA · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183479 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 2 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing